In a strategic effort to advance precision immunotherapies for autoimmune diseases, Genentech has entered into an exclusive collaboration and licensing agreement with Repertoire Immune Medicines to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Through the deal, which involves a US$35 M upfront payment and up to US$765 M in milestones, Genentech gains rights to Repertoire’s DECODE™ platform, which maps T cell receptor-antigen interactions to uncover disease specific immune drivers. This partnership reflects Genentech’s broader strategy to expand its immunology pipeline with innovative, mechanism-driven therapies.